VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
INGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
INGNInogen, Inc.
$6.03$163M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
INGN logo

Inogen, Inc.

INGN
NASDAQ · Medical Devices
$6.03
At close - Nov 6, 4:00 PM EST - USD
Market Cap$163M
P/E-4.5x
52W High$7.67
Volume974.91K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Inogen's Margins Erode Amid Structural Growth Slowdown

Inogen's year-over-year revenue growth has decelerated from 8.1% in 2024Q1 to 3.0% in 2026Q2, while gross margin has fluctuated between 44.1% and 50.8% and fell to 45.5% in the latest quarter, suggesting pricing and input-cost headwinds may persist.

GrowthDecelerating
ProfitabilityStrained
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

INGN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-115% Peers

P/E is 115% below peer median

03

Market leadership

RS 63 · Avg

Average momentum (RS Rating: 63)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
INGN-9.05%
S&P 500 (^GSPC)+7.63%
1-Year Return
INGN-14.22%
S&P 500 (^GSPC)+9.69%
3-Year Return
INGN+14.20%
S&P 500 (^GSPC)+51.88%
5-Year Return
INGN-83.89%
S&P 500 (^GSPC)+45.49%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-4.5x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-4.5x
N/A
N/A
EV/EBITDA
N/A
18.0x
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$349M+3.9% YoY
Net income FY25
-$23M+36.6% YoY
Free cash flow FY25
-$22M-93.2% YoY
Operating margin FY25
-8.7%+4.0 pts YoY
ROIC (FY25)-24.4%
Avg ROIC 5Y-33.7%
ROE (TTM)-20.1%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.56-293.5%
vs -$0.14
$77M-16.3%
vs $92M
Q3 2026
Aug 6, 2026
-$0.14+8.7%
vs -$0.15
$95M-0.2%
vs $95M
Q2 2026
May 7, 2026
-$0.30-25.0%
vs -$0.24
$85M+3.4%
vs $82M
Q1 2026
Feb 24, 2026
-$0.26+27.8%
vs -$0.36
$82M-3.9%
vs $85M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·1d ago
Inogen, Inc. (INGN) Q3 2026 Earnings Call Transcript

Inogen, Inc. ( INGN ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Lorna Williams - Senior Vice President of Investor Relations Andrew Reding - President, CEO & Director Jason Richardson - CFO, Executive VP & Treasurer Presentation Operator Welcome to Inogen's Third Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, November -- as a reminder, this conference is being recorded today, November 5, 2026.

MarketBeat·2d ago
What Inogen (INGN) Said on Its Q3 Earnings Call

Inogen NASDAQ: INGN reported lower third-quarter revenue as weaker spending by large European customers offset a return to growth in U.S. sales. The respiratory care company also outlined a $20 million annualized cost-reduction program following the sale of its U.S. oxygen rental business.

Business Wire·3d ago
Inogen Announces Third Quarter 2026 Financial Results

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Appoints Andy Reding as President and Chief Executive Officer; Company initiates a $20 million cost reduction program to accelerate profitability.

Business Wire·3d ago
Inogen Announces Leadership Transition

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Leadership Transition; Chief Operating Officer Andy Reding Appointed President and Chief Executive Officer.

Filtered for Inogen, Inc.More Headlines
04

Compare before deciding

Benchmark INGN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Inogen, Inc. (INGN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
INGN logoINGNInogen, Inc.Current
$6.03$163.26M-4.503.86%-10.46%-20.06%—
LNTH logoLNTHLantheus Holdings, Inc.
$100.61$6.55B25.500.5%17.28%21.72%—
CRVL logoCRVLCorVel Corporation
$83.16$4.24B34.697.03%12.02%30.2%—
APOG logoAPOGApogee Enterprises, Inc.
$45.77$955.14M14.263.21%4.68%13.03%2.26%
PHM logoPHMPulteGroup, Inc.
$132.49$25.57B13.85-3.54%11.24%13.8%0.67%
LUNG logoLUNGPulmonx Corporation
$2.56$108.13M-2.608.01%-47.93%-98.23%—

Compare INGN vs Peers

Inogen, Inc. (INGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LNTH

Most directly comparable listed peer for INGN.

Scale Benchmark

vs LIN

Larger-name benchmark to compare INGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs LNTH, CRVL, APOG, PHM

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

INGN SEC Filings & Documents

Inogen, Inc. (INGN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jul 1, 2026·SEC

Material company update

Jun 11, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 28, 2025·SEC

FY 2024

Mar 1, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 7, 2026·SEC

FY 2026

May 8, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when INGN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

INGN Frequently Asked Questions

Inogen, Inc. (INGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Inogen, Inc.'s revenue?

Inogen, Inc. (INGN) reported $339.1M in revenue over the trailing twelve months. Revenue was $348.7M in fiscal year 2025. That is 1038% more than the $30.6M of fiscal year 2011.

How fast is Inogen, Inc. growing?

Inogen, Inc. (INGN) revenue fell by 2.3% over the trailing twelve months, compared with the twelve months before.

Is INGN profitable?

No. Inogen, Inc. (INGN) reported a net loss of $35.5M over the trailing twelve months.

Dividend & Returns
What is INGN's return on equity?

Inogen, Inc. (INGN) had a return on equity (ROE) of -20.1% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Inogen, Inc.'s free cash flow?

Inogen, Inc. (INGN) had negative free cash flow of $16.9M over the trailing twelve months.

What if you invested $1,000 in INGN back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →